A recent study from the Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; The James Cancer Hospital, The Ohio State University, Columbus, OH, USA shows that Transcription factor foxo1 is a negative regulator of NK cell maturation and function. This study was published in the 10 March 2015 issue of Immunity (the number 1 journal in the field of Immunological research with an impact factor of 19.748) by Prof Yu J, Deng Y, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based Immune augmentation therapy: AbM (Agaricus blazei Murill), a medicinal mushroom, promotes NK cell maturation and function via down regulation of its target gene
Significance:
This study suggests, for the first time, a natural product-based NK-cell therapy: AbM, by increasing the expression of its target gene, it may decrease the expression of FOXO1. Thereby, it may promote NK cell maturation and function. Thus, pharmacological formulations encompassing “Agaricus blazei Murill or small molecule compounds isolated from it” may be used to (1) increase NK cell function; and (2) eradicate large solid tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based Immune augmentation therapy: AbM (Agaricus blazei Murill), a medicinal mushroom, promotes NK cell maturation and function via down regulation of its target gene, 20/April/2014, 8.47 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How AbM decreases Foxo1 expression and increases NK cell function.
